Payment overview · 2025
General Payments
$4,300.95
239 reported records · 29 companies
Healthcare provider profile · identity verified
Daljit Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PITTSBURGH, PA · NPI 1952364044
Verified facts
What the public records show
CMS Open Payments records show Daljit Singh, M.D. received $4,300.95 in general payments during 2025 across 239 reported records.
GlaxoSmithKline, LLC. accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Paxlovid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 331 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 515 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $530.39 | 12.3% | 26 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $491.28 | 11.4% | 27 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $408.13 | 9.5% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $378.60 | 8.8% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $332.01 | 7.7% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $312.20 | 7.3% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $274.64 | 6.4% | 13 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $179.57 | 4.2% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $175.93 | 4.1% | 15 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $169.34 | 3.9% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $120.32 | 2.8% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $87.13 | 2.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.75 | 2.0% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.32 | 2.0% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $75.25 | 1.8% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.94 | 1.6% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $60.42 | 1.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.55 | 1.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.55 | 1.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.34 | 1.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.78 | 1.1% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.59 | 1.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.04 | 1.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.86 | 0.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.06 | 0.9% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $23.66 | 0.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.60 | 0.5% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $20.40 | 0.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $19.30 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,300.95 | 239 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $530.39 | 26 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $316.54 | 16 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $239.27 | 13 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $239.27 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $219.50 | 12 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $212.59 | 12 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $179.57 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $179.00 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $179.00 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $178.61 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $175.93 | 15 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $169.34 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $169.10 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $165.05 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $160.75 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $140.71 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $134.03 | 8 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $99.69 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $95.16 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $87.13 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $75.25 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $68.94 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $64.64 | 4 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $60.42 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $59.55 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $51.34 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $50.84 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.90 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $42.59 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $37.42 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 51 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 191 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 125 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 37 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
137 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
83 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 26 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
146 | 145 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
46 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
331 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
191 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
125 | 23 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
515 | 96 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1244 | 258 |
| Atorvastatin Calcium | Atorvastatin Calcium | 981 | 258 |
| Levothyroxine Sodium | Levothyroxine Sodium | 956 | 240 |
| Pantoprazole Sodium | Pantoprazole Sodium | 899 | 284 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 818 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 809 | 213 |
| Furosemide | Furosemide | 728 | 192 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 716 | 97 |
| Lorazepam | Lorazepam | 567 | 115 |
| Diclofenac Sodium | Diclofenac Sodium | 524 | 163 |
| Eliquis | Apixaban | 515 | 96 |
| Valsartan | Valsartan | 507 | 136 |
| Metoprolol Succinate | Metoprolol Succinate | 493 | 119 |
| Quetiapine Fumarate | Quetiapine Fumarate | 488 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 443 | 114 |
| Meloxicam | Meloxicam | 427 | 123 |
| Potassium Chloride | Potassium Chloride | 425 | 105 |
| Sertraline Hcl | Sertraline Hcl | 408 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 389 | 111 |
| Famotidine | Famotidine | 386 | 129 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 377 | 94 |
| Omeprazole | Omeprazole | 357 | 92 |
| Alprazolam | Alprazolam | 341 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 332 | 86 |
| Xarelto | Rivaroxaban | 331 | 63 |
| Repaglinide | Repaglinide | 326 | 76 |
| Metformin Hcl | Metformin Hcl | 317 | 93 |
| Allopurinol | Allopurinol | 302 | 76 |
| Trazodone Hcl | Trazodone Hcl | 292 | 68 |
| Azelastine Hcl | Azelastine Hcl | 291 | 114 |
| Losartan Potassium | Losartan Potassium | 290 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 288 | 70 |
| Prednisone | Prednisone | 284 | 157 |
| Tramadol Hcl | Tramadol Hcl | 281 | 102 |
| Carvedilol | Carvedilol | 259 | 71 |
| Irbesartan | Irbesartan | 253 | 71 |
| Duloxetine Hcl | Duloxetine Hcl | 241 | 55 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 226 | 51 |
| Baclofen | Baclofen | 224 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 62 |
| Simvastatin | Simvastatin | 218 | 61 |
| Telmisartan | Telmisartan | 211 | 56 |
| Mirtazapine | Mirtazapine | 208 | 59 |
| Jardiance | Empagliflozin | 191 | 37 |
| Spironolactone | Spironolactone | 187 | 46 |
| Oxycodone Hcl | Oxycodone Hcl | 186 | 53 |
| Bupropion Hcl Sr | Bupropion Hcl | 185 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 178 | 36 |
| Bumetanide | Bumetanide | 177 | 51 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 169 | 50 |
| Lisinopril | Lisinopril | 166 | 47 |
| Azithromycin | Azithromycin | 161 | 134 |
| Cephalexin | Cephalexin | 159 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 52 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 156 | 40 |
| Clonidine Hcl | Clonidine Hcl | 149 | 42 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 149 | 41 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 146 | 145 |
| Pregabalin | Pregabalin | 141 | 24 |
| Mupirocin | Mupirocin | 140 | 97 |
| Synthroid | Levothyroxine Sodium | 137 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 132 | 31 |
| Labetalol Hcl | Labetalol Hcl | 127 | 31 |
| Mounjaro | Tirzepatide | 125 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 123 | 28 |
| Tradjenta | Linagliptin | 123 | 19 |
| Celecoxib | Celecoxib | 120 | 31 |
| Methocarbamol | Methocarbamol | 118 | 46 |
| Ezetimibe | Ezetimibe | 117 | 41 |
| Ondansetron Hcl | Ondansetron Hcl | 115 | 47 |
| Digoxin | Digoxin | 109 | 20 |
| Finasteride | Finasteride | 107 | 25 |
| Ibuprofen | Ibuprofen | 107 | 38 |
| Levetiracetam | Levetiracetam | 107 | 24 |
| Nifedipine Er | Nifedipine | 107 | 30 |
| Ozempic | Semaglutide | 107 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 34 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 102 | 19 |
| Warfarin Sodium | Warfarin Sodium | 102 | 26 |
| Amoxicillin | Amoxicillin | 99 | 79 |
| Atenolol | Atenolol | 99 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 98 | 76 |
| Ondansetron Odt | Ondansetron | 94 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 17 |
| Nystatin | Nystatin | 92 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 85 | 26 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 83 | 22 |
| Bupropion Xl | Bupropion Hcl | 83 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 54 |
| Myrbetriq | Mirabegron | 83 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 81 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 61 |
| Buspirone Hcl | Buspirone Hcl | 78 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 33 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 74 | 12 |
| Donepezil Hcl | Donepezil Hcl | 73 | 17 |
| Farxiga | Dapagliflozin Propanediol | 73 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 55 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 23 |
| Cilostazol | Cilostazol | 69 | 14 |
| Bupropion Hcl | Bupropion Hcl | 67 | 15 |
| Memantine Hcl | Memantine Hcl | 65 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 64 | 19 |
| Valacyclovir | Valacyclovir Hcl | 64 | 35 |
| Montelukast Sodium | Montelukast Sodium | 63 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 14 |
| Alendronate Sodium | Alendronate Sodium | 60 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 19 |
| Meclizine Hcl | Meclizine Hcl | 60 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 16 |
| Clonazepam | Clonazepam | 59 | 13 |
| Midodrine Hcl | Midodrine Hcl | 57 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 55 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 37 |
| Fluconazole | Fluconazole | 54 | 30 |
| Entresto | Sacubitril/Valsartan | 51 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 50 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | 27 |
| Fenofibrate | Fenofibrate,micronized | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 20 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 48 | 13 |
| Glimepiride | Glimepiride | 47 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Lidocaine | Lidocaine | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 44 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 42 | 13 |
| Latanoprost | Latanoprost | 42 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 41 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 40 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 16 |
| Olanzapine | Olanzapine | 39 | 18 |
| Ibu | Ibuprofen | 38 | 16 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Hydrocortisone | Hydrocortisone | 35 | 18 |
| Ketoconazole | Ketoconazole | 35 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lactulose | Lactulose | 34 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Potassium Citrate Er | Potassium Citrate | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 33 | 11 |
| Topiramate | Topiramate | 33 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 31 | 11 |
| Levofloxacin | Levofloxacin | 31 | 26 |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Metronidazole | Metronidazole | 30 | 17 |
| Mirabegron Er | Mirabegron | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 19 |
| Tolterodine Tartrate | Tolterodine Tartrate | 30 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Buprenorphine | Buprenorphine | 28 | suppressed |
| Methadone Hcl | Methadone Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 21 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 26 | 23 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | 12 |
| Nyamyc | Nystatin | 25 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 23 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 18 |
| Clonidine | Clonidine | 21 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 12 |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 16 |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 17 | 17 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 16 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Acetic Acid | Acetic Acid | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Glatopa | Glatiramer Acetate | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,300.95 · 239 records | GlaxoSmithKline, LLC. | ABRYSVO, ACCRUFER, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBI, ENTRESTO, FARXIGA, FFRct, FREESTYLE LIBRE 3, INJECTAFER, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, LEQVIO, LifeVest, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, PAXLOVID, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, REXULTI, SPRAVATO, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, UNITHROID, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XHANCE, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error